1 Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms 2 collected by the Covid Symptoms Study App

- 3
- 4 Carole H. Sudre^{1,2,3}, Benjamin Murray³, Thomas Varsavsky³, Mark S. Graham³, Rose S. Penfold⁴,
- 5 Ruth C. Bowyer⁵, Joan Capdevila Pujol⁵, Kerstin Klaser³, Michela Antonelli³, Liane S. Canas³,
- 6 Erika Molteni³, Marc Modat³, M. Jorge Cardoso³, Anna May⁵, Sajaysurya Ganesh⁵, Richard
- 7 Davies⁵, Long H Nguyen⁶, David A. Drew⁶, Christina M. Astley⁷, Amit D. Joshi⁶, Jordi Merino^{8,9,10},
- 8 Neli Tsereteli¹¹, Tove Fall¹², Maria F. Gomez¹¹, Emma L. Duncan⁴, Cristina Menni⁴, Frances M.K.
- 9 Williams⁴, Paul W. Franks^{4,11}, Andrew T. Chan⁶, Jonathan Wolf⁵, Sebastien Ourselin^{3*}, Tim
- 10 Spector⁴^{*}, Claire J. Steves⁴^{*}*
- 11
- 12 1 MRC Unit for Lifelong Health and Ageing, Department of Population Health Sciences,
- 13 University College London, WC1E 7HB London
- 14 2 Centre for Medical Image Computing, Department of Computer Science, University College
- 15 London
- 3 School of Biomedical Engineering & Imaging Sciences, King's College London, SE1 7EU, London
 UK
- 18 4 Department of Twin Research and Genetic Epidemiology, King's College London,
- 19 Westminster Bridge Road, SE17EH London, UK
- 20 5 Zoe Global Limited, 164 Westminster Bridge Road, London SE1 7RW, UK
- 21 6 Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, MA, USA
- 7 Division of Endocrinology & Computational Epidemiology, Boston Children's Hospital, MA,
 USA
- 8Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston,
 MA, USA.
- 26 9Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA.
- 27 10Department of Medicine, Harvard Medical School, Boston, MA, USA.
- 28 11 Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Sweden
- 12 Molecular epidemiology, Department of Medical Sciences, Uppsala University, SE-751 85
 30 Uppsala Sweden
- 31
- 32 * Contributed equally
- 33 Corresponding author: Claire J. Steves Claire.j.steves@kcl.ac.uk
- 34
- 35
- 36 Reports of "Long-COVID", are rising but little is known about prevalence, risk factors, or
- 37 whether it is possible to predict a protracted course early in the disease. We analysed data
- 38 from 4182 incident cases of COVID-19 who logged their symptoms prospectively in the COVID
- 39 Symptom Study app. 558 (13.3%) had symptoms lasting >=28 days, 189 (4.5%) for >=8 weeks

It is made available under a CC-BY-NC-ND 4.0 International license .

40	and 95 (2.3%) for >=12 weeks. Long-COVID was characterised by symptoms of fatigue,
41	headache, dyspnoea and anosmia and was more likely with increasing age, BMI and female
42	sex. Experiencing more than five symptoms during the first week of illness was associated
43	with Long-COVID, OR=3.53 [2.76;4.50]. A simple model to distinguish between short and long-
44	COVID at 7 days, which gained a ROC-AUC of 76%, was replicated in an independent sample
45	of 2472 antibody positive individuals. This model could be used to identify individuals for
46	clinical trials to reduce long-term symptoms and target education and rehabilitation services.
47	
48	COVID-19 can manifest a wide severity spectrum from asymptomatic to fatal forms ¹ . A further
49	source of heterogeneity is the duration of symptoms, which could have considerable impact
50	due to the huge scale of the pandemic. Hospitalised patients are well recognised to have lasting
51	dyspnoea and fatigue in particular ² , yet such patients constitute the 'tip of the iceberg' of
52	symptomatic SARS CoV2 disease ³ . Few studies capture symptoms prospectively in the general
53	population to ascertain with accuracy the duration of illness and the prevalence of long-lasting
54	symptoms.
55	
56	Here we report a prospective observational cohort study of COVID-19 symptoms in a subset of
57	4182 users of the COVID Symptom Study app meeting inclusion criteria (see online methods) 4,5 ,
58	compared to matched symptomatic test-negative controls. Briefly, the cases comprised
59	individuals who reported testing positive for SARS-CoV2 by swab testing who started on the
60	app "feeling physically normal" to be able to determine symptom onset. We compare cases

61 with symptoms persisting over 28 days, LC28) and short duration (symptoms lasting less than

It is made available under a CC-BY-NC-ND 4.0 International license .

62	10 days, short-COVID). Our previous findings that clusters of symptoms predicted the need for
63	acute care ⁶ led us to hypothesize that persistent symptomatology in COVID-19 (Long-COVID) is
64	associated with early symptom patterns which could be used to predict who might be affected.
65	Figure 1 shows the duration of symptoms reported in COVID+ cases (orange) over-laid on age,
66	sex and BMI matched negative-testing symptomatic controls (blue). The overall median
67	symptom duration was 11 days (IQR[6;19]).
68 69	Of the 4182 COVID-19 swab positive users, 558 (13.3%) met the LC28 definition (Median 41,
70	IQR[33,63]) of whom 189 (4.5%) met LC56, and 108 (2.6%) LC84. In contrast 1591 (38.0%) had
71	short-COVID (median 6, IQR[4-8]). The proportions were comparable in three countries (LC28:
72	GB 13.3%, USA 16.1%, Sweden 12.1% p=0.35; LC56: GB 4.7%, USA 5.5%, Sweden 2.5% p=0.07).
73	
74	Table 1 summarises the descriptive characteristics of the study population stratifying by
75	symptom/disease duration. Age was significantly associated with LC28, rising from 9.9% in 18-
76	49 year-olds to 21.9% in those aged >=70 (p < 0.0005), with escalating OR by age decile (Figure
77	1b, Supplementary Table 2). LC28 disproportionately affected women (14.9%) compared to
78	men (9.5%), although not in the older age-group. Long-COVID affected all socio-economic
79	groups (assessed using Index of Multiple Deprivation), (Supplementary Figure 2). Individuals
80	with Long-COVID were more likely to have required hospital assessment. Asthma was the
81	only/unique pre-existing condition providing significant association with LC28 (OR=2.14 [1.55-
82	2.96]).
83 84	

It is made available under a CC-BY-NC-ND 4.0 International license .

86	Fatigue (97.7%) and headache (91.2%) were the most reported symptoms in those with LC28,
87	followed by anosmia and lower respiratory symptoms, and headache was more often reported
88	intermittently (Figure 2, supplementary Table s1). Free-text additional symptoms were more
89	commonly reported in LC28 cases (81%) compared to Short-COVID (45%), with cardiac
90	symptoms (palpitations, tachycardia) (LC28,6.1%; short-COVID 0.5% p <0.0005), concentration
91	or memory issues (4.1% vs 0.2%, p<0.0005), tinnitus and earache (3.6% vs 0.2% p<0.0005) and
92	peripheral neuropathy symptoms (pins and needles and numbness) (2% vs 0.5% p=0.004)
93	disproportionately reported in LC28. Most of these symptoms were reported for the first time
94	3-4 weeks post-symptom onset.
95	
96	We found two main patterns of symptomatology within LC28: those reporting exclusively
97	fatigue, headache and upper respiratory complaints (shortness of breath, sore throat,
98	persistent cough and loss of smell) and those with additional multi-system complaints, including
99	ongoing fever and gastroenterological symptoms (Supplementary figure 3). In the individuals
100	with long duration (LC28), ongoing fever OR 2.16 [1.50;3.13] and skipped meals OR 2.52
101	[1.74;3.65] were strong predictors of a hospital visit. Details of the frequency of symptoms
102	persisting beyond 28 and 56 days after disease onset are provided in Supplementary table 3.
103	
104	
105	Individuals with LC28 were more likely to report relapses (16.0% vs 8.4%) (p<0.0005). In
106	comparison, in the matched group of SARS-CoV2 negative-tested individuals, relapse was
107	reported in 11.5%, and relapse was longer in LC28 (median = 9 [5-18] vs 6 [4-10] days).
108	

It is made available under a CC-BY-NC-ND 4.0 International license .

109	We explored how to estimate risk of LC28 among positive individuals from data available early
110	in the disease course. Individuals reporting more than 5 symptoms in the first week (the
111	median number reported) were significantly more likely to go on to experience LC28, (OR=3.95
112	[3.10;5.04]). This strongest risk factor was predictive in both sexes and all age groups
113	(supplementary Figures 4, a-e).
114	
115	The five symptoms experienced during the first week most predictive of LC28 in the positive
116	individuals were: fatigue OR=2.83 [2.09;3.83], headache OR=2.62 [2.04;3.37], dyspnoea
117	OR=2.36 [1.91;2.91], hoarse voice OR=2.33 [1.88;2.90] and myalgia OR=2.22 [1.80;2.73] (Figure
118	3). Similar patterns were observed in both genders. In adults aged over 70, loss of smell (which
119	is less common) was the most predictive of long-COVID OR=7.35 [1.58;34.22] before fever
120	OR=5.51 [1.75;17.36] and hoarse voice OR=4.03[1.21;13.42] (Supplementary figures 4). Co-
121	occurrence plots of symptoms in short-COVID versus LC28 further illustrate the importance of
122	early multi-symptom involvement (Figure 3c).
123 124	We created Random Forest Prediction models using a combination of the first week's symptom
125	reporting, personal characteristics and comorbidities. Using all features, the average ROC AUC
126	was 76.7% (SD=2.5) (Figure 3d) in the classification between short-COVID and LC28. The
127	strongest predictor was age (29.2%) followed by the number of symptoms during the first week
128	(16.3%). Feature importance was relatively similar across age-specific models. However, in the
129	over 70s, early features such as fever, anosmia and comorbidities were important, and may be
130	'red flags' in older adults (Supplementary figure 6).

It is made available under a CC-BY-NC-ND 4.0 International license .

132	To create a model usable in healthcare settings, we simplified the prediction model to include
133	only symptom number in the first week with age, and sex in a logistic regression model
134	obtaining ROC AUC of 76.7% (SD 2.5) (Figure 3d), for which the calibration slope had an average
135	of 1.02 (0.15). When optimising the balance between false positives and false negatives, we
136	obtained a specificity of 73.4% (SD 9.7) and a sensitivity of 68.7% (SD 9.9). Specificity,
137	Sensitivity, PPV and NPV values at different thresholds are presented in Supplementary table 6.
138	
139	Key predictive findings of our analysis were validated in an independent dataset of 2412
140	individuals who reported testing antibody positive (but no positive PCR result) for SARS-CoV2
141	from 2 weeks after symptom onset where, again, the number of symptoms in the first week of
142	illness was the strongest predictor, OR=4.60 [95% CI 3.28; 6.46]. The simple prediction model,
143	was similarly predictive of LC28 in the antibody group, with a ROC-AUC of 75.9% (SD=4.3%)
144	(Figure 3-e).
145	
146	While this study provides important insights into the disease presentation, any generalisation
147	should be considered carefully. Our study was limited by being confined to app users who were
148	disproportionately female and under-represented those >70years which could increase or
149	decrease our estimate of the extent of Long-COVID respectively and caution is needed in
150	interpreting associations found in smaller population subgroups. Swab test results were self-
151	reported and were all assumed to be RT-PCR, as antigen tests were not available at the time.
152	Applying a weighting following the UK population (see Supplementary Methods), the estimated
153	proportion of people experiencing symptomatic COVID-19 going on to suffer Long-COVID were

It is made available under a CC-BY-NC-ND 4.0 International license .

154 similar: 14.5%, 5.1% and 2.2% for 4, 8- and 12-weeks duration respectively. While estimates 155 could be inflated because early PCR testing was restricted to those more severely unwell, or if 156 regular logging or test results encouraged a systematic bias in symptom reporting. Long-COVID 157 may here be underestimated if individuals with prolonged symptoms were more likely to stop 158 logging symptoms on the app. Our participant selection criteria were chosen to confidently 159 identify cases, and upper and lower bounds for estimates given each exclusion criteria are 160 presented in Supplementary Table 4. Symptom reporting rates through the study period for all 161 users are also presented in Supplementary Table 6. Taken together, these data suggest that our 162 estimates may be conservative. We had insufficient numbers to explore risk factors for disease 163 over 2 months and were unable to analyse the impact of ethnicity due to incomplete data. In 164 addition, the list of symptoms on the app is necessarily non-exhaustive, however, analysis of 165 the free-text responses allowed us to highlight other symptoms present in Long-COVID, such as 166 cardiac and neurological manifestations. With emerging evidence of ongoing myocardial inflammation and change in^{8,9} associated with COVID-19, this calls for specific studies of cardiac 167 168 and neurological longer-term sequelae of COVID-19.

169

At the population level, it is critical to quantify the burden of Long-COVID to better assess its impact on the healthcare system and appropriately distribute resources. In our study, prospective logging of a wide range of symptoms allowed us to conclude that the proportion of people with symptomatic COVID-19 who experience prolonged symptoms is considerable, and relatively stable across three countries with different cultures. Whether looking at a four-week or an eight-week threshold for defining long duration, those experiencing Long-COVID were

It is made available under a CC-BY-NC-ND 4.0 International license .

176	consistently older, more likely to be female and to require hospital assessment than in the
177	group reporting symptoms for a short period of time. Those going on to experience LC28 had
178	multi-system disease from the start, supporting the need for holistic support ¹⁰ . While asthma
179	was not reported as a factor of risk for hospitalisation in ¹¹ , its association with Long-COVID
180	(LC28) warrants further investigation.
181	
182	We found early disease features were predictive of duration. With only three features - number
183	of symptoms in the first week, age and sex, we were able to accurately distinguish individuals
184	with LC28 from those with short duration. Importantly, the model generalised well to the
185	population reporting antibody testing. This important information could feature in highly
186	needed targeted education material for both patients and healthcare providers and we present
187	typical nomograms for use in clinical settings in Supplementary Figure 7. Moreover, the method
188	could help determine at-risk groups and could be used to target early intervention trials and
189	clinical service developments to support rehabilitation in primary and specialist care ¹⁴ to
190	alleviate Long-COVID and facilitate timely recovery.
191 192 193 194 195 196 197 198	Ethics: In the UK, the App Ethics has been approved by KCL ethics Committee REMAS ID 18210, review reference LRS-19/20-18210 and all subscribers provided consent. In Sweden, ethics approval for the study was provided by the central ethics committee (DNR 2020-01803). Funding: Zoe provided in kind support for all aspects of building, running and supporting the app and service to all users worldwide. Support for this study was provided by the NIHR-funded Biomedical Research Centre based at GSTT NHS Foundation Trust. This work was supported by the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Pased Healthcare
200 201 202	Investigators also received support from the Wellcome Trust, the MRC/BHF, Alzheimer's Society, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in partnership with KCL. ATC was supported in this work

- 203 through a Stuart and Suzanne Steele MGH Research Scholar Award. CM is funded by the
- 204 Chronic Disease Research Foundation and by the MRC AimHy project grant. LHN, DAD, ADJ,

It is made available under a CC-BY-NC-ND 4.0 International license .

- ADS, CG, WL are supported by the Massachusetts Consortium on Pathogen Readiness
- 206 (MassCPR) and Mark and Lisa Schwartz. JM was partially supported by the European
- 207 Commission Horizon 2020 program (H2020-MSCA-IF-2015-703787). The work performed on the
- 208 Swedish study is supported by grants from the Swedish Research Council, Swedish Heart-Lung
- 209 Foundation and the Swedish Foundation for Strategic Research (LUDC-IRC 15-0067).
- 210 **Competing interests**:
- 211 Zoe Global Limited co-developed the app *pro bono* for non-commercial purposes. Investigators
- received support from the Wellcome Trust, the MRC/BHF, EU, NIHR, CDRF, and the NIHR-
- 213 funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in
- 214 partnership with KCL. RD, JW, JCP, AM and SG work for Zoe Global Limited and TDS and PWF
- 215 are consultants to Zoe Global Limited. LHN, DAD,JM, PWF and ATC previously participated as
- 216 investigators on a diet study unrelated to this work that was supported by Zoe Global Ltd.
- 217 **Data and materials availability:** Data used in this study is available to bona fide researchers
- 218 through UK Health Data Research using the following link
- 219 https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259
- 220

221

222 References

- Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C.
 Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019
 (COVID-19): A Review. JAMA Journal of the American Medical Association vol. 324 782–
 793 (2020).
- Sheehy, L. M. Considerations for postacute rehabilitation for survivors of COVID-19.
 Journal of Medical Internet Research vol. 22 (2020).
- 230 3. Alwan, N. A. A negative COVID-19 test does not mean recovery. *Nat. 2020 5847820*231 (2020).
- 2324.Menni, C. *et al.* Real-time tracking of self-reported symptoms to predict potential COVID-23319. Nat. Med. **26**, 1037–1040 (2020).
- 2345.Drew, D. A. *et al.* Rapid implementation of mobile technology for real-time epidemiology235of COVID-19. *Science (80-.).* eabc0473 (2020) doi:10.1126/science.abc0473.
- Sudre, C. H. *et al.* Symptom clusters in Covid 19: A potential clinical prediction tool from
 the COVID Symptom study app. *medRxiv* 2020.06.12.20129056 (2020)
 doi:10.1101/2020.06.12.20129056.
- 239
 7.
 Cirulli, E. T. *et al.* Long-term COVID-19 symptoms in a large unselected population.

 240
 medRxiv (2020) doi:10.1101/2020.10.07.20208702.
- 8. Mitrani, R. D., Dabas, N. & Goldberger, J. J. COVID-19 cardiac injury: Implications for long term surveillance and outcomes in survivors. *Hear. Rhythm* (2020)
 doi:10.1016/j.hrthm.2020.06.026.
- Padda, I., Khehra, N., Jaferi, U. & Parmar, M. S. The Neurological Complexities and
 Prognosis of COVID-19. *SN Compr. Clin. Med.* (2020) doi:10.1007/s42399-020-00527-2.
- 246 10. Living with Covid19. https://evidence.nihr.ac.uk/themedreview/living-with-covid19/

247		(2020) doi:10.3310/themedreview_41169.			
248	11.	Robinson, L. B. et al. Title: COVID-19 severity in asthma patients: A multi-center matched			
249		cohort study. <i>medRxiv</i> 2020.10.02.20205724 (2020) doi:10.1101/2020.10.02.20205724.			
250	12.	Mahase, E. Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes			
251		preprint. <i>BMJ</i> 369 , m2512 (2020).			
252	13.	Beigel, J. H. <i>et al</i> . Remdesivir for the Treatment of Covid-19 — Preliminary Report. <i>N</i> .			
253		<i>Engl. J. Med.</i> (2020) doi:10.1056/nejmoa2007764.			
254	14.	Greenhalgh, T., Knight, M., A'Court, C., Buxton, M. & Husain, L. Management of post-			
255		acute covid-19 in primary care. <i>BMJ</i> 370 , (2020).			
256	15.	Drew, D. A. et al. Rapid implementation of mobile technology for real-time epidemiology			
257		of COVID-19. <i>Science (80)</i> . (2020).			
258	16.	Spiel, C. et al. A Euclidean distance-based matching procedure for non randomized			
259		comparison studies. <i>Eur. Psychol.</i> 13 , 180–187 (2008).			
260					
261					
262					
263					
264					
265	Table 1. Characteristics of Individuals with COVID-19 by duration of symptoms, compared to				
266	match	ned sample testing negative for COVID-19. In statistical comparison, the short COVID			
267	group is the reference.				
268					

	Positive PCR test				Matched Negative
	Short (<10 days)	LC28 (>=28 days) (including LC56)	LC56 (>=56 days)	Overall	sample
Number	1591	558	189	4182	4182
GB/SE/US [numbers, %]	1365 / 139 / 87 85.8 / 8.7 / 5.5	466/57/35 83.5 / 10.2 / 6.3	165/12/12 87.3 / 6.3 / 6.3	3491 / 473 / 218 83.5 / 11.3 / 5.2	3882/131/169 92.8/3.1/4.1
Male (%)	32.7	20.3***	16.9*	28.5	28.5
Age (years) [median, IQR]	38 [29;49]	50 [39;57]***	52 [43;59]***	42 [32;53]	42 [32;53]
Age group (18-49/ 50-69/ >70)	1122/331/38 75.3 / 22.2 / 2.5	259/262/24 47.5 / 48.1 / 4.4	69/96/11 39.2 / 54.5 / 6.3	2627/1195/96 62.8 / 28.6 / 2.3	2821 / 1264/97 67.5 / 30.2 / 2.3
Obese (%)	23.8	27.6*	26.5	26.3	26.4
BMI (kg/m²) [median, IQR]	25.5 [22.7;29.7]	26.1 [23.3;30.5]	25.9[23.3;30.5]	25.9[23.3;30.3]	25.9 [23.0;30.3]
Asthma (%)	7.7	15.8***	18.0***	10.0	13.7
Lung disease (%)	12.8	16.5**	15.9	13.6	13.7
Diabetes (%)	3.0	3.9	5.8*	2.9	2.8
Heart (%)	1.7	3.2**	4.8**	1.9	1.7

It is made available under a CC-BY-NC-ND 4.0 International license .

Kidney (%)	0.5	0.9	0.5	0.6	0.6
IMD (median decile - IQR)	7 [4;9]	7 [5;9]	7 [5;9]	7 [4;9]	7[5;9]***
IMD quintiles	64/75/334/132/634 5.2/6.1/27.0/10.7/51.2	23/23/86/49/240 5.5/5.5/20.4/11.6/57.0	10/9/26/18/88 6.6/6.0/17.2/11.9/58.3	158 / 194 /830/363 /1653 4.9 /6.1/26.0/11.4/51.7	118/193/895/376/2057 3.2/5.3/24.6/10.3/56.5
Visit to hospital (%)	7.0	31.5***	43.9***	13.9	4.1
Number of symptomsin the first week [median [IQR]]	5 [3;7]	7 [5-9]***	7 [5;9]***	6 [4;8]	3 [2;4]***

269 * indicates p <0.1 ** <0.05 ***<0.01 when comparing to short covid. Comparison are performed with respect to

the "short duration" within the positive group. Matched Negatives are compared to the overall positive population

Mann Whitney U tests are performed for continuous variables and chi square tests are performed when

comparing proportions.

Index of Multiple Deprivation (IMD) information is only available for app users from the UK who have entered a
 complete post code

275 Acronyms: GB – Great Britain / SE – Sweden / US – United States / IMD – Index of multiple deprivation

- 276
- 277



Figure 1. a) Distribution of duration of symptoms in COVID-19 – The coloured bars indicate the limits to define short, LC28 and LC56. The y-axis reports the normalised frequency of duration of symptoms. b) OR and 95% CI of LC28 with each successive decile compared to 20-30-year-olds

- 283
- 284

It is made available under a CC-BY-NC-ND 4.0 International license .

DE - Duration Short DE - Number reports Short Duration LC28 Number reports LC28 Duration LC56 Number reports LC56





Figure 2: Symptoms by duration. For each symptom (ordered from top to bottom by increasing frequency of
 occurrence) the median duration of report is presented by the total (hollowed) bar height, with associated
 interquartile range represented by the black line, for the short, LC28 and LC56 durations. The filled bars represent
 the number of times a report has been given. For both duration and number of reported days of symptoms, the x
 axis reflects the number of days. This highlights the differences in the symptoms in terms of their intermittence
 throughout the course of the disease. (Abbreviations DE – delirium, AP – Abdominal Pain, HV – Hoarse Voice, DI –
 Diarrhoea, CP – Chest Pain, SM – skipped meals, UMP – Unusual Muscle pains, FV – Fever, ST – Sore Throat, PC –
 Persistent Cough, LOS – Loss of smell, SOB – Shortness of breath, HA – Headache, FA – Fatigue)

- 294
- 295
- 296

It is made available under a CC-BY-NC-ND 4.0 International license .



297 298

299

300 Figure 3: Symptom correlates of long-COVID for LC28 (a) and LC56 (b) with correction for age and gender. c) Co-301 occurrence network of symptom pairs with the frequency of symptom report as the size of the node and the 302 likelihood of symptom pair co-occurrence by the weight of the edge linking them. Edges representing a co-303 occurrence of less than 10% were removed. d) – Receiver Operating Characteristic (ROC) curve of the cross-304 validated full and reduced models on the PCR cohort. e)- ROC curve when training on the whole PCR cohort and 305 testing on the antibody-positive cohort for the full (blue) and reduced (magenta) model. Random predictive 306 probability is indicated in both panels as a dashed red line. (Abbreviations DE – delirium, AP – Abdominal Pain, HV 307 - Hoarse Voice, DI - Diarrhoea, CP - Chest Pain, SM - skipped meals, UMP - Unusual Muscle pains, FV - Fever, ST -308 Sore Throat, PC – Persistent Cough, LOS – Loss of smell, SOB – Shortness of breath, HA – Headache, FA – Fatigue)

- 309
- 310
- 311
- 312

It is made available under a CC-BY-NC-ND 4.0 International license .

313